For Providers
Anatomic pathology
Urological Pathology
Your trusted leader in genitourinary testing services.
Gastrointestinal Pathology
Your trusted leader in GI/Liver testing services.
Myeloid68 uses targeted next-generation sequencing (NGS) to detect somatic alterations in 68 genes associated with myeloid malignancies.
Chronic Lymphocytic Leukemia
GoPath Laboratories offers a complete testing solution for your CLL patients, including morphology, flow cytometry, FISH, cytogenetics, lgVH testing, B-cell receptor stereotyping, and minimal residual disease monitoring.
Test Menu
Full Service Test Menu
Molecular, FISH, Flow Cytometry, Histology, Cytology
For Individuals
Prostate cancer
Prostate cancer patient guide
PROSTATENOW™ is a genetic test for men with prostate cancer or those at risk of developing prostate cancer.
Breast & Ovarian cancer
Breast Cancer Patient Guide
BRCANOW® is a next-generation sequencing panel for people with a personal or family history of breast or ovarian cancer.
Colon cancer
Colon Cancer Patient Guide
LYNCHNOW® is a germline screening tool to test for Lynch syndrome and other hereditary cancer disorders in patients with colorectal cancer.
For Providers
PROSTATENOW™ Physician Brochure
PROSTATENOW™ is a clinical grade comprehensive germline panel offered by GoPath Diagnostics.
Dr. Brian Helfand
Brian T. Helfand, MD, Ph.D.; Division Head of Urology – NorthShore Medical Group
The core of germline testing is to know which genes/mutations have clinical validity and utility. The genes tested in PROSTATENOW™ are based on a combination of clinical guidelines and up-to-date evidence-based review.
Dr. Jim Lu
Jim Lu MD, Ph.D.; President, CEO and Medical Director; 15+ Years of Experience in GI and Liver Pathology
Dr. Jianfeng Xu
Jianfeng Xu, DrPH; Vice President, Translational Research; Director, Program for Personalized Cancer Care
Prostate Cancer Flyer
A Comprehensive Germline Panel for Prostate Cancer
HGG Advances
Genetic factors associated with prostate cancer conversion from active surveillance to treatment
European Association of Urology
Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis
BRCANOW Gene list
BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform developed exclusively at GoPath Laboratories.
LynchNow® Flyer
GoPath offers a comprehensive step-by-step and cost-effective lynch screening program.
GeneticsNow® Gene List
Bringing solutions to genetic testing. GoPath's GeneticsNow® Series includes a collection of next-generation sequencing panels that detect germline variants associated with an increased risk for various hereditary cancers.
Genetic Counseling
Genetic Counselor Dani Bishay
Dani Bishay, MS, CGC. Certified Genetic Counselor. 10+ Years in Genetic Counseling.
Genetic Counselor TinaMarie Bauman
TinaMarie Bauman RN, MSN, APN, AGN-BC. Hereditary Cancer Genetics Nurse. 20+ Years of Experience in Genetics Counseling and Oncology Nursing.
Genetic Counselor Scott M. Weissmann
Scott M. Weissmann, MS, CGC. Certified Genetic Counselor. 15+ Years in Genetic Counseling.
Genetic Counseling
Next Generation of Hereditary Genetic Testing
For Individuals
OncoTarget®500 Patient Guide
OncoTarget® 500 is a comprehensive genomic profiling panel that analyzes over 500 genes to detect genomic alterations known to alter cancer growth.
For Providers
OncoTarget®500 Physician brochure
FDA-Cleared IVD Comprehensive Genomic Profiling Panel.
OncoTarget®500 Tech Sheet
Genomic Profiling Powered by GoPath Diagnostics.
OncoTarget®500 Infopage
Unique Advantages of OncoTarget500®. Fast. Proven. Actionable.
Infopage - OncoTracking™
Monitor Treatments. Early Treatment. Track.
  • #ASCO22 week is here and we are excited to announce the release of our FDA-Cleared CGP Test under OncoTarget® 500.

    Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.